or Try an Advanced Search...

    Cord Blood Stocks List

    Symbol Grade Name % Change
    CCEL A Cryo-Cell International, Inc. -0.59
    BLFS D BioLife Solutions, Inc. -2.91
    FATE F Fate Therapeutics, Inc. -2.88
    THMO F ThermoGenesis Holdings, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology Medical Care Facilities Medical Devices Medical Instruments & Supplies
    Related Stock Lists: Biology Stem Cell Life Sciences Adult Stem Cell Biotechnology Blood Childbirth Cryopreservation Umbilical Cord Biopharmaceutical Blood Cells Bone Bone Marrow Cell Biology Chimeric Antigen Receptor Clinic Clinical Applications Clinical Development Drug Discovery FDA

    Related ETFs - A few ETFs which own one or more of the above listed Cord Blood stocks.

    Symbol Grade Name Weight
    WDNA D WisdomTree BioRevolution Fund 1.09
    CNCR F Loncar Cancer Immunotherapy ETF 0.78
    PTH D Invesco DWA Healthcare Momentum ETF 0.77
    PSCH C PowerShares S&P SmallCap Health Care Portfolio 0.59
    FYC B First Trust Small Cap Growth AlphaDEX Fund 0.37
    View all Cord Blood ETFs...
    Compare ETFs
    Compare CNCR to FYC Compare PTH to FYC Compare PTH to PSCH

        Cord Blood Stocks Recent News

        Date Stock Title
        Nov 15 FATE Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
        Nov 15 BLFS BioLife Solutions, Inc. (NASDAQ:BLFS) Just Reported And Analysts Have Been Cutting Their Estimates
        Nov 14 BLFS BioLife Solutions sells its Custom Biogenic Systems freezer subsidiary for $6.1M
        Nov 14 BLFS BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary
        Nov 14 FATE Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 14 BLFS BioLife Solutions Third Quarter 2024 Earnings: Beats Expectations
        Nov 13 FATE FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
        Nov 13 BLFS BioLife Solutions Inc (BLFS) Q3 2024 Earnings Call Highlights: Strategic Divestitures and ...
        Nov 13 BLFS BioLife Solutions, Inc. (BLFS) Q3 2024 Earnings Call Transcript
        Nov 12 FATE Fate Therapeutics GAAP EPS of -$0.40 beats by $0.01, revenue of $3.07M beats by $1.63M
        Nov 12 BLFS BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Tops Revenue Estimates
        Nov 12 FATE Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates
        Nov 12 FATE Fate Therapeutics: Q3 Earnings Snapshot
        Nov 12 BLFS BioLife Solutions GAAP EPS of -$0.04 beats by $0.04, revenue of $30.6M beats by $5.2M
        Nov 12 BLFS BioLife Solutions Reports Third Quarter 2024 Financial Results
        Nov 12 FATE Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
        Nov 12 BLFS BioLife sells SciSafe for $73 million
        Nov 12 BLFS BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary
        Nov 12 BLFS Earnings Scheduled For November 12, 2024
        Nov 11 BLFS BioLife Solutions Q3 2024 Earnings Preview
        Related Industries: Biotechnology Medical Care Facilities Medical Devices Medical Instruments & Supplies
        Related Stock Lists: Biology Stem Cell Life Sciences Adult Stem Cell Biotechnology Blood Childbirth Cryopreservation Umbilical Cord Biopharmaceutical Blood Cells Bone Bone Marrow Cell Biology Chimeric Antigen Receptor Clinic Clinical Applications Clinical Development Drug Discovery FDA
        Cord Blood

        Cord blood is the blood that remains in the umbilical cord and placenta after a baby is born. It is a rich source of stem cells, which are used to treat a variety of medical conditions. Cord blood can be collected and stored for potential future use in a process known as cord blood banking.

        Browse All Tags